Sign in
CompletedNo phase

Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis

Key facts

Who runs it
Prince of Songkla University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
1 Jun 2024
Ended
28 Feb 2025
Type of study
Observational
Record updated
24 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Participants aging over 18 years old with the symptoms of systemic inflammatory response syndrome (SIRS) which requires at least two of the following symptoms
  • Temperature over 38 degree Celsius (Fever) or lower than 36 degree Celsius (hypothermia)
  • Tachycardia
  • Tachypnea, or the detection of PaCO2 under 32 mmHg, or hypocapnia due to hyperventilation
  • Participants are about to received Ceftriaxone by the physician
  • Weighting equal to or more than 50 kg

Who cannot take part

  • Patients received Ceftriaxone within 3 days before the participation
  • Having CLcr lower than 50 ml/min, or receiving hemodialysis, or renal replacement therapy
  • Patients with the clinical record of the severe allergy to β-lactam or Ceftriaxone
  • Decompensated liver disease
  • Having the level of serum albumin lower than 2.5 g/dl
  • Having a culture result of being resistant to Ceftriaxone
  • Meningitis patients
  • Pregnant and lactating
  • Septic shock patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

As the general treatment method for infectious diseases is to prescribe antibiotics which can be complete at the empirical treatment with the control of the sources of infection, the types of antibiotics that contain the broad spectrum and the proper dose to reduce the severity of infection play an important role. Especially, patients with sepsis should receive antibiotics within 1 hours after the diagnosis since the delay of 1 hour will decrease the rate of survival by 7.6 percent. Ceftriaxone is considered to be Cephalosporin, the antibiotics in the group of β-lactams antibiotic which kills bacteria by preventing the creation of significant cell walls. Ceftriaxone is soluble and can be excreted by the kidney. It is a β-lactams broad spectrum which can kill bacteria broadly including various types of gram-positive and gram-negative. The effectiveness of Ceftriaxone is in accord with the percentage of time that the level of the drug is beyond the minimum inhibitory concentration. According to the research in animals conducted by Craig WA and others, the drug effect to prevent the bacteria growth will occur when the %ft>MIC is more than at least 40%. The rate of prevention will reach the maximal bactericidal effect when the %ft>MIC is equal to 60 to 70%. At the moment, physicians prefer the 60 to 70% of %ft>MIC in the group of Cephalosporins drugs as the main pharmacodynamics to cope with infections.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 November 2025